Difference between revisions of "Team:Duke"

Line 13: Line 13:
 
</style>
 
</style>
  
<img src="https://static.igem.org/mediawiki/2015/f/f7/Duke_iGEM_Logo.jpg" width="837" height="600" align="center"/>
+
<img src="https://static.igem.org/mediawiki/2015/f/f7/Duke_iGEM_Logo.jpg" width="700" height="550" align="middle"/>
  
 
<h2 class="head"> Overview </h2>
 
<h2 class="head"> Overview </h2>

Revision as of 22:58, 18 September 2015



Overview

Background

Cas9

Cas9 is a protein originally from within the Streptococcus pyogenes immune response system. Cas9, with the Clustered Regularly Interspersed Palindromic Repeats (CRISPR) and other CRISPR-associated proteins were initially used to respond to known pathogenic genetic information. In its native form, it will cut the invasive protein at recognized spots before it can incorporate into the bacteria. Fragments of new viral DNA is saved into a library of DNA fragments which is the CRISPR, named after the repeated loop structure between each fragment. Once these are transcribed and processed, the construct of copied nucleic acid sequence and loop is known as a short guide RNA, or gRNA.

However, because of the ease and predictability of the targeting, the protein has been used as a useful and controllable DNA targeting construct. This level of control has been honed in by modifying the protein to only cut one strand. These nickases require two successful Cas9 landings to fully cut the DNA. Additionally, functional groups such as transcription activators and repressors have been attached to make a deactivated Cas9 protein (dCas9) a programmable activator protein. Because the wide variety of CRISPR systems in bacteria, multiple independent systems can be implemented in the same biological chassis.

dCas9 Repression

From this, Duke iGEM has had an interest in a phenomemon associated with dCas9 called CRISPR interference, where the presence of the large dCas9 protein blocks the RNA polymerase from continuing, knocking down transcription rates.[1] Our project incorporates many of the findings present in this paper. The paper finds that cumulative repression of multiple gRNA binding sites is stronger than additive, but not quite as strong as multiplicative. The paper also found that targets farther down the gene from the promoter feature weaker repression.

Decoy Binding Sites

Building off these results, we attempted to look at what happens if multiple sites compete for the same gRNA sequence. As would be expected, the more decoy sites that are present, the weaker the repression on the reporter sequence. We theorized that the effect was due to a molecular titrating effect where the new binding sites remove the dCas9 from equilibrium from the reporter sequence.